We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » AMARILLO BIOSCIENCES SUBMITS IND FOR IDIOPATHIC PULMONARY FIBROSIS TREATMENT

AMARILLO BIOSCIENCES SUBMITS IND FOR IDIOPATHIC PULMONARY FIBROSIS TREATMENT

July 7, 2006

Amarillo Biosciences has announced that it submitted an investigational new drug (IND) application to the FDA to begin a study of orally delivered interferon alpha in 60 patients with idiopathic pulmonary fibrosis (IPF).

IPF patients will be enrolled from approximately six clinical sites in the U.S. The patients will be given interferon or placebo for four weeks to assess the effect of treatment on chronic cough. Approximately 85 to 90 percent of IPF patients complain of a bothersome persistent cough that negatively impacts their quality of life. This trial is a follow-up to a positive pilot study conducted by investigators at the Texas Tech University Health Sciences Center, in which five out of six IPF patients given orally administered IFN-alpha reported a significant reduction in chronic cough with corresponding improvement in their quality of life.

KEYWORDS Drug Pipeline Alert

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 13Sep

    Trial Master File Inspection Readiness: From Chaos to Calm

  • 14Sep

    Omnichannel Engagement: Are You Digitally Ready?

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Guardant Health Receives FDA Approval for Guardant360 CDx Liquid Biopsy Test

  • Genentech Inks Licensing Deal With Jemincare Over Androgen Receptor Degrader

  • FDA Clears Thermo Fisher Scientific’s Wheat and Sesame Allergy Tests

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing